Meeting
2011 ASCO Annual Meeting
Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC).
Authors
T. Stinchcombe
University of North Carolina at Chapel Hill, Chapel Hill, NC
T. Stinchcombe , M. A. Socinski , D. T. Moore , S. N. Gettinger , R. H. Decker , W. J. Petty , A. W. Blackstock , G. Schwartz , S. Lankford , D. E. Morris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Local-regional and Adjuvant Therapy/Small Cell
Track
Lung Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT00280150
Citation
J Clin Oncol 29: 2011 (suppl; abstr 7016)
Abstract #
7016
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa).
First Author: Howard Jack West
Poster
2022 ASCO Annual Meeting
Checkpoint inhibitor consolidation after definitive chemoradiation for stage III non–small cell lung cancer: Real-world experience in a large academic health system.
First Author: Nikhil Yegya-Raman
Poster
2022 ASCO Annual Meeting
FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.
First Author: Rita Migliorino
Poster
2020 ASCO Virtual Scientific Program
Angiogenesis inhibitor plus erlotinib versus erlotinib alone as first-line for advanced non-small cell lung-cancer harboring EGFR mutation.
First Author: Thierry Landre